Literature DB >> 18538135

Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications.

Evi N Debruyne1, Joris R Delanghe.   

Abstract

Hepatocellular carcinoma is the 5th most common cancer in the world. Prognosis for this disease is poor since hepatocellular carcinoma is mostly diagnosed at an advanced stage. Serum alpha-fetoprotein (AFP) is one of the most common diagnostic markers for hepatocellular carcinoma. However, its diagnostic value is more and more questioned. Therefore, research has focussed on AFP related parameters (AFP mRNA and AFP glycoforms). The aim of this paper is to review the present knowledge on AFP and its related parameters in diagnosing and monitoring HCC. AFP related parameters can be arranged in two types: AFP mRNA and AFP glycoforms. AFP mRNA is a potentially prognostic marker and AFP mRNA assays are based on PCR techniques. The AFP glycoforms have diagnostic potential and assays are based on isoelectric focussing and lectin affinity electrophoretic methods. Up to now the diagnostic use of the AFP related parameters is limited. Although some of them are recommended as a complementary test, they cannot (yet) replace serum AFP as the golden standard of diagnostic markers for hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538135     DOI: 10.1016/j.cca.2008.05.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  60 in total

Review 1.  Emerging actions of the nuclear receptor LRH-1 in the gut.

Authors:  Pablo J Fernandez-Marcos; Johan Auwerx; Kristina Schoonjans
Journal:  Biochim Biophys Acta       Date:  2010-12-29

2.  Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.

Authors:  Chunlei Li; Baobao Song; Patricia M Santos; Lisa H Butterfield
Journal:  Cell Immunol       Date:  2018-11-01       Impact factor: 4.868

3.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

4.  Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.

Authors:  Lin Chen; Feihu Chu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-04-24

Review 5.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma.

Authors:  Min Dong; Zhan-Hong Chen; Xing Li; Xiao-Yun Li; Jing-Yun Wen; Qu Lin; Xiao-Kun Ma; Li Wei; Jie Chen; Dan-Yun Ruan; Ze-Xiao Lin; Tian-Tian Wang; Dong-Hao Wu; Xiang-Yuan Wu
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

7.  Identifying causal regulatory SNPs in ChIP-seq enhancers.

Authors:  Di Huang; Ivan Ovcharenko
Journal:  Nucleic Acids Res       Date:  2014-12-17       Impact factor: 16.971

8.  The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.

Authors:  Yukiyasu Okamura; Ryo Ashida; Takaaki Ito; Teiichi Sugiura; Keita Mori; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2014-12-20       Impact factor: 2.549

9.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

10.  Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.

Authors:  Jia Fan; Guang-Shun Yang; Zhi-Ren Fu; Zhi-Hai Peng; Qiang Xia; Chen-Hong Peng; Jian-Ming Qian; Jian Zhou; Yang Xu; Shuang-Jian Qiu; Lin Zhong; Guang-Wen Zhou; Jian-Jun Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.